Histograft, part of Artgen Biotech, has started clinical trials of gene-activated osteoplastic material for the treatment of patients with degenerative-dystrophic spine diseases. Material is already approved for clinical use in trauma practice, but to date no clinical data have been accumulated for large-scale introduction of the product into this segment of medical indications.